Condition
Horton's Disease
Total Trials
5
Recruiting
0
Active
0
Completed
4
Success Rate
80.0%-7% vs avg
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
80.0%
-6.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
25%
1 of 4 completed with results
Key Signals
1 with results80% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 1 (1)
Trial Status
Completed4
Terminated1
Trial Success Rate
80.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT02158208CompletedPrimary
Study of the T CD8 Immune Response in Horton's Disease
NCT02857192Not ApplicableCompletedPrimary
Study of Phenotypic and Functional Characteristics of Regulatory T Lymphocytes in Horton's Disease
NCT04390126Completed
COVID-19 Related Lockdown Effects On Chronic Diseases
NCT02955147Phase 1Terminated
Ustekinumab for the Treatment of Giant Cell Arteritis
NCT02065297CompletedPrimary
Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD)
Showing all 5 trials